Drug intelligence / Profile preview

c-MET short hairpin RNA lentivirus

Development stage
Preclinical
Lead developer
Luoyang Polytechnic
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

c-MET short hairpin RNA lentivirus is an experimental gene therapy agent designed to silence the expression of the c-MET (mesenchymal-epithelial transition) receptor, the high-affinity tyrosine kinase receptor for hepatocyte growth factor (HGF). Delivered via a lentiviral vector, the shRNA triggers RNA interference (RNAi) to degrade c-MET mRNA, leading to a significant reduction in c-MET protein levels. In the context of chronic lymphocytic leukemia (CLL), this knockdown disrupts the HGF/c-MET signaling axis, which normally promotes cell survival through the activation of AKT, ERK, and STAT3 pathways. The resulting inhibition of these pro-survival signals downregulates anti-apoptotic BCL-2 family proteins (such as BCL-2, MCL-1, and BCL-xL), arrests the cell cycle, and induces apoptosis in leukemic cells. This approach is being explored as a potential therapeutic strategy to overcome microenvironment-mediated drug resistance in CLL.

Other names
c-MET-shRNA lentivirusshRNA-c-MET lentiviruslentivirus-mediated c-MET shRNA
02

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on c-MET short hairpin RNA lentivirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on c-MET short hairpin RNA lentivirus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call